Quidelortho Corp quarterly report, Q3 FY2022

Business context and reporting period

QuidelOrtho Corporation’s unaudited third-quarter 2022 Form 10-Q covers the 13 weeks ended October 2, 2022; year-to-date figures cover 39 weeks. The May 27, 2022 combination of Quidel and Ortho materially changed the company’s scale and business mix. Ortho’s results are included only from the acquisition date, so reported year-over-year comparisons are not fully like-for-like.

Financial performance and position

• Revenue rose 54% in Q3 and 126% year to date. Acquisition-related revenue was a major contributor; Ortho generated $700.4 million in revenue and a $63.6 million net loss from closing through October 2.
• Calculated Q3 operating margin was approximately 7.2% versus 55.3% a year earlier; nine-month operating margin was approximately 31.6% versus 49.9%. Q3 net margin was approximately 2.4% versus 42.3%; nine-month net margin was approximately 21.6% versus 38.9%.
• Cost of sales excluding intangible amortization was 48.0% of Q3 revenue versus 26.4% a year earlier, and 38.0% year to date versus 25.9%. Results included $35.4 million of Q3 and $46.6 million of year-to-date expense from the acquired inventory fair-value step-up.
• Cash and cash equivalents were $212.2 million at October 2, down from $802.8 million at January 2. Cash, cash equivalents and marketable securities totaled $284.3 million; working capital including cash and current marketable securities was $572.5 million.
• Borrowings totaled $2,689.6 million, including $207.6 million current and $2,482.0 million long term. The $800 million revolving facility had $781.8 million available after letters of credit. The company reported compliance with debt covenants.
• Operating cash flow was $715.9 million year to date. Investing cash outflow was $1,584.9 million, primarily reflecting $1,511.4 million of acquisition payments net of cash acquired. Financing cash inflow was $283.7 million.

Material changes versus prior period

• Q3 Point-of-Care revenue fell 39% to $270.5 million, mainly on lower SARS assay demand and lower BNP sales following transition of the BNP business to Beckman. Molecular Diagnostics revenue declined 72% to $15.4 million, primarily from lower Lyra SARS assay demand and pricing.
• Acquired Labs and Transfusion Medicine contributed $334.8 million and $163.1 million of Q3 revenue, respectively; these businesses had little or no comparable revenue in the prior-year presentation.
• Q3 interest expense increased to $29.7 million from $1.3 million, primarily due to acquisition financing. Year-to-date results included a $24.0 million loss on extinguishment of debt and $109.6 million of acquisition and integration costs.
• Year-to-date COVID-19 products represented 54% of revenue, down from 71% in the prior-year period. Influenza products accounted for 7%, up from 3%. Four largest customers together represented approximately 48% of revenue in both year-to-date periods.
• Cash declined substantially following the combination, while goodwill and intangible assets rose to $2,357.7 million and $3,223.9 million, respectively, largely reflecting acquisition accounting.

Outlook, commentary and risks

• No specific numeric revenue or earnings guidance is provided. Management expected COVID-19 test demand to fluctuate and pricing pressure to continue, and said Q3 demand declines could mark a transition toward an endemic environment. It anticipated revenue growth in core products excluding COVID-19 tests for the rest of 2022, while noting influenza demand depends on flu-season severity.
• Management cited supply shortages, shipping and logistics delays, inflation, labor constraints and rising costs as ongoing challenges that could affect production, fulfillment and results. China lockdowns had affected operations, though impacts were not material to year-to-date results.
• Other notable exposures include the uncertain pace of COVID-19 demand, customer and product concentration, foreign-exchange movements, variable-rate debt and integration of Ortho. Management said available cash, operating cash flow and borrowing capacity should cover near-term needs for at least 12 months.
• The company had $2,750 million of variable-rate term debt and hedging instruments; it entered into additional interest-rate swaps after quarter-end. Foreign-currency translation reduced comprehensive income by $92.9 million in Q3 and $158.9 million year to date.
• Management said current legal matters in aggregate were not expected to have a material adverse effect, while noting outcomes or increased accruals in one or more matters could materially affect results or cash flows. Disclosure controls were considered effective; integration of acquired-business controls was ongoing.

Important facts for investors to verify

• Separate acquisition-driven growth from underlying organic performance, especially in Labs, Transfusion Medicine and geographic segments.
• Track COVID-19 testing demand, pricing and product concentration, alongside core and influenza product trends.
• Assess whether integration costs, acquired inventory step-up charges and acquired Ortho losses subside as expected.
• Monitor debt repayment, interest costs, covenant headroom, interest-rate hedges and liquidity following the cash decline.
• Review the final purchase-price allocation, including acquired intangible values, useful lives, goodwill and related deferred taxes; these estimates remained preliminary.
• Evaluate ongoing supply-chain constraints, customer concentration and foreign-exchange effects on revenue, margins and cash flows.